Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akebia Therapeutics

3.97
+0.28007.59%
Post-market: 4.000.0299+0.75%19:50 EDT
Volume:8.18M
Turnover:31.90M
Market Cap:1.04B
PE:-19.15
High:4.00
Open:3.66
Low:3.66
Close:3.69
Loading ...

Richard C. Malabre, SVP and Chief Accounting Officer, Reports Disposal of Common Shares of Akebia Therapeutics Inc

Reuters
·
06 Jun

Akebia Therapeutics Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $8

THOMSON REUTERS
·
04 Jun

Akebia Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
04 Jun

BRIEF-Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
03 Jun

Akebia Therapeutics’ Growth Potential Driven by Vafseo’s Market Expansion and Upcoming VALOR Trial

TIPRANKS
·
30 May

Akebia Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Stock Track | Akebia Therapeutics Soars 5.28% Pre-market on Stellar Q1 Earnings, Beating Estimates

Stock Track
·
08 May

Akebia Therapeutics Q1 EPS $0.03 Beats $(0.04) Estimate, Sales $57.34M Beat $44.88M Estimate

Benzinga
·
08 May

Akebia Therapeutics Q1 EPS USD 0.03 VS. Ibes Estimate USD -0.04

THOMSON REUTERS
·
08 May

Akebia Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
06 May

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 May

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
02 May

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
01 May

Akebia Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
28 Apr

Leerink Partners Initiates Coverage on Akebia Therapeutics With Outperform Rating, $7 Price Target

MT Newswires Live
·
28 Apr

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock

Zacks
·
10 Apr

US High Growth Tech Stocks to Watch in 2023

Simply Wall St.
·
09 Apr

Akebia Therapeutics Price Target Maintained With a $7.50/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment

MT Newswires Live
·
03 Apr

BRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months

Reuters
·
03 Apr